Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Journal of Diabetes Investigation
|
October 7, 2017
Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial
Arihiro Kiyosue, Yutaka Seino, Keiji Nishijima, et al.
Journal of Diabetes Investigation
|
December 27, 2017
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial
Shizuka Kaneko, Keiji Nishijima, Heidrun Bosch-Traberg, et al.
Diabetes Care
|
June 18, 2016
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
Michael Nauck, Manfredi Rizzo, Andrew Johnson, et al.
Journal of Diabetes Investigation
|
March 14, 2022
A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
Yutaka Seino, Hideaki Miyoshi, Heidrun Bosch Traberg, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
November 5, 2018
Liraglutide and Glycaemic Outcomes in the LEADER Trial
Bernard Zinman, Michael A Nauck, Heidrun Bosch-Traberg, et al.
Journal of Diabetes Investigation
|
May 17, 2016
Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial
Yutaka Seino, Shizuka Kaneko, Shuichi Fukuda, et al.
Journal of Diabetes Investigation
|
January 28, 2016
Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial
Kohei Kaku, Arihiro Kiyosue, Yuri Ono, et al.
Kidney International Reports
|
July 31, 2024
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
Katherine R Tuttle, Stephen C Bain, Heidrun Bosch-Traberg, et al.
Cardiovascular Diabetology
|
August 24, 2023
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Peter Rossing, Stephen C Bain, Heidrun Bosch-Traberg, et al.
Kidney International
|
August 20, 2023
The authors reply
Katherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Journal of Diabetes Investigation
|
October 7, 2017
Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial
Arihiro Kiyosue, Yutaka Seino, Keiji Nishijima, et al.
Journal of Diabetes Investigation
|
December 27, 2017
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial
Shizuka Kaneko, Keiji Nishijima, Heidrun Bosch-Traberg, et al.
Diabetes Care
|
June 18, 2016
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
Michael Nauck, Manfredi Rizzo, Andrew Johnson, et al.
Journal of Diabetes Investigation
|
March 14, 2022
A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
Yutaka Seino, Hideaki Miyoshi, Heidrun Bosch Traberg, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
November 5, 2018
Liraglutide and Glycaemic Outcomes in the LEADER Trial
Bernard Zinman, Michael A Nauck, Heidrun Bosch-Traberg, et al.
Journal of Diabetes Investigation
|
May 17, 2016
Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial
Yutaka Seino, Shizuka Kaneko, Shuichi Fukuda, et al.
Journal of Diabetes Investigation
|
January 28, 2016
Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial
Kohei Kaku, Arihiro Kiyosue, Yuri Ono, et al.
Kidney International Reports
|
July 31, 2024
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
Katherine R Tuttle, Stephen C Bain, Heidrun Bosch-Traberg, et al.
Cardiovascular Diabetology
|
August 24, 2023
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Peter Rossing, Stephen C Bain, Heidrun Bosch-Traberg, et al.
Kidney International
|
August 20, 2023
The authors reply
Katherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, et al.
Page
of 3